AbCellera Biologics
ABCL
ABCL
203 hedge funds and large institutions have $1.3B invested in AbCellera Biologics in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 79 increasing their positions, 58 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
7% more funds holding
Funds holding: 190 → 203 (+13)
1.99% more ownership
Funds ownership: 42.73% → 44.73% (+2%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Holders
203
Holding in Top 10
6
Calls
$19M
Puts
$7.75M
Top Buyers
| 1 | +$64.2M | |
| 2 | +$13M | |
| 3 | +$9.81M | |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$7.22M |
| 5 |
CC
Casdin Capital
New York
|
+$6.28M |
Top Sellers
| 1 | -$19.9M | |
| 2 | -$8.7M | |
| 3 | -$5.09M | |
| 4 |
Millennium Management
New York
|
-$4.47M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$4.21M |